IFNK and systemic lupus erythematosus: IFN-κ, an IFN-I that is highly expressed by lupus keratinocytes (Tsoi et al., 2019), reduced LC ADAM17 sheddase activity by nearly 40% when used to treat LCs ex vivo (Figure 5C).